3M Corporation - Allegations Of Recklessness Over Trials Of BacLite To Detect MRSA 'Superbug' Infection
Friday, May 13, 2011 - 15:20
in Health & Medicine
The Porton Group, the private equity partner of the British Ministry of Defence, has accused 3M Corporation of "negligence and possible recklessness putting lives at risk" due to "botched" 2007 clinical trials of a medical device called "BacLite," which can detect within five hours the presence of the potentially deadly MRSA/staph "superbug." The trials were conducted after notification of the U.S. Food and Drug Administration (FDA) and after seeking FDA advice, which 3M proceeded to ignore, according to Porton. As a result, Baclite was withdrawn and the group that sold it to 3M are blaming 3M. read more